Načítá se...
Restraining CDK1–cyclin B activation: PP2A on the cUSP(7)
USP7 inhibitors are gaining momentum as a therapeutic strategy to stabilize p53 through their ability to induce MDM2 degradation. However, these inhibitors come with an unexpected p53‐independent toxicity, via an unknown mechanism. In this issue of The EMBO Journal, Galarreta et al report how inhibi...
Uloženo v:
| Vydáno v: | EMBO J |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8167361/ https://ncbi.nlm.nih.gov/pubmed/33969907 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/embj.2021108486 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|